Organization
Incyte Biosciences International Sarl
1 abstract
Abstract
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.Org: Moores Cancer Center, UC San Diego Health, University of California San Diego, La Jolla, CA, Institut Curie, Saint Cloud, France, Paris, France,